Lucentis and hypertension combos among new Japanese launches
This article was originally published in Scrip
Japan has listed a number of important new therapies on its national health insurance reimbursement tariff, including Lucentis and two antihypertensive combinations for which peak annual sales are expected to top $400 million.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.